TY - JOUR T1 - LATE-BREAKING ABSTRACT: Challenging immunosuppression treatment in lung transplant patients with kidney failure: Rescue therapy with basiliximab? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA1786 VL - 46 IS - suppl 59 SP - PA1786 AU - Neeraj Kohli AU - Kirsty Habibi-Parker AU - Haifa Lyster AU - Anna K. Reed AU - Martin Carby AU - Andre R. Simon AU - Aron F. Popov AU - Simona Soresi Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA1786.abstract N2 - Introduction: Kidney failure after lung transplantation (LTX) is a recognised risk factor for chronic kidney disease and worse long term outcomes. Calcineurin-inhibitors (CNI) play a major role in terms of possible kidney dysfunction after LTX in the early postoperative course, especially in combination with antimicrobial drugs. Sirolimus is not recommended due to the surgical healing process and also RATG are associated with higher risk of infection and sepsis. We report our preliminary experience with anti-interleukin-2 monoclonal antibody Basiliximab,as a “CNI-free window”Methods: Nine LTX patients with kidney failure requiring haemodialysis for >14 days were included. Basiliximab was administrated according to the protocol(Day 0,4, and 20).Tacrolimus was discontinued or the dose reduced to maintain a level between 2-4 ng/ml. Daily monitoring of kidney function and levels of tacrolimus were performed.Results: Baseline eGFR pre-transplant was normal in all patients. Seven patients completely recovered from kidney failure and were switched back on Tacrolimus without complications(mean eGFR pre and post basiliximab 22.4 and 64.3 mmol/min). Two patients did not survived and showed also no recovery from kidney failure(1x lobar transplant and 1x transplanted from long-term ECMO).Out of seven patients who showed a response to treatment, six were discharge home, whilst the remaining one is still with on-going rehabilitation.Conclusion: Basiliximab might be a safe and feasible therapeutical option in patients which are affected by CNI-related kidney failure in the immediate post lung transplant period. Further studies are necessary to confirm our preliminary results. ER -